AbbVie looks cheap at 16 times earnings, against the 20 times drugmakers usually get. Fair value is $285.91 to $363.89, based on 20 times next year's $16.25 a share give or take 12%, so the $261.83 price sits 8% below the low end; it turns expensive above $307.61. The range leans on forecasts, with forward earnings 60% above trailing. This is a levels-only read off reported earnings and estimates, with no fundamental work. x.com 

Moderna, biotech stocks, AbbVie and Amgen have bullish chart setups. Their daily charts are in uptrends, with the latest strong bullish candles confirming momentum alongside steady, strong whale accumulation. x.com 

AbbVie's terminal value is a concern: it has had big autoimmune hits to backfill Humira, yet it still trades at 19x forward earnings on a $450B market cap, while Johnson & Johnson's 2024-25 acquisition spree is paying off. x.com 

The healthcare sector, including Moderna, AbbVie, Johnson & Johnson and Merck, looks ready to push higher off Moderna's cancer news. x.com 

Eli Lilly's fundamentals are on very strong footing. Q2 revenue rose 48% year over year to $23B as demand for Zepbound and Mounjaro keeps up, and the oral GLP-1 pill Foundayo completed its first full quarter. The company raised its full-year revenue guidance to $85-87B, its second raise this year. The chart is now setting up for a breakout. x.com 

Abivax's risk-reward still makes a ton of sense because buyout comps point to a large premium. @seedy19tron's analysis suggests a 105% premium to the current price, about $218 a share or roughly $20 billion, would get a deal over the line for Pfizer, Lilly, Takeda, AbbVie or AstraZeneca. x.com 

Bristol Myers Squibb offers a strong drug pipeline and a 4.3% dividend, making it a slow but safe long-term holding. It sits in one of the market's largest bullish ascending triangles, with a 350% gain projected to complete Wave 5. x.com